Arthneeti
RB

Rossari Biotech Ltd

Q1 FY26Chemicals & Petrochemicals

Rossari Biotech Ltd Q1 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Q1 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹502
Market cap₹2.8K Cr
P/E18.5
Updated23 Aug 2026
Read4 min read

The short version

Rossari Biotech expects mid-double-digit revenue growth of around 14%-15% annually over the next 2 years. Rossari Biotech expects mid-double-digit (14%-15%) growth in both revenue and EBITDA over the next 2 years (Page 8).

From Rossari Biotech Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Rossari Biotech expects mid-double-digit revenue growth of around 14%-15% annually over the next 2 years.
  • Export sales are anticipated to make up approximately 27%-28% of overall turnover on an annualized basis.
  • The Institutional Cleaning and Consumer Business vertical is expected to grow healthily on an annual basis, especially in subsequent quarters after Q1.
  • The B2B business is projected to grow at a faster pace over the next 2-3 years once EO availability improves and new capacities attain optimal utilization.
  • Volume growth in exports has been 11% YoY despite temporary disruptions, indicating robust demand.
  • Capacity expansion projects are underway and expected to deliver 3x-4x asset turnover and margin expansion from FY27 onwards.
  • The overseas formulation facility in Southeast Asia will support future international growth and stronger customer engagement in the region.

Profitability & Margins

See what Rossari Biotech Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Ongoing capacity expansion projects across Rossari Biotech, Unitop Chemicals, and Tristar Intermediates progressing in phases.
  • These expansions aim to eliminate capacity constraints, enhance supply chain agility, and strengthen positioning in high-growth sectors.
  • Commissioning of new capacities expected in upcoming quarters, with full operation and optimal utilization anticipated by FY27, delivering 3x-4x asset turns.
  • An overseas formulation facility is being set up in Southeast Asia with an initial CAPEX of around Rs. 15-20 crore to enhance international presence and customer engagement.
  • Investments are funded through a mix of internal accruals and debt.
  • CAPEX work impacted production temporarily due to safety protocols but is on track.
  • Full benefit of expanded Ethylene Oxide (EO) capacity expected mostly from September-October 2026, with capacity ramp-up continuing over 3-4 years.
  • Focus on phased commissioning and strategic investments to drive scalable and profitable growth from FY27 onwards.

Top-ranked in Chemicals & Petrochemicals

Ranked on what management guided this quarter

5x potential
1Shiv Texchem
Rev 1Mar 2
2Yasho Industries
Rev 1Mar 3
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Rossari Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • The company did not provide specific figures regarding the current or expected orderbook/pending orders during the call.
  • It was mentioned that some institutional orders are phased and expected to be fulfilled over the next couple of quarters, indicating a pipeline of pending orders.
  • The Institutional Consumer business experienced a softer Q1 but is expected to show healthy growth on an annual basis.
  • Q2 and Q3 are anticipated to be stronger quarters for fulfilling institutional orders.
  • Export orders missed in Q1 due to production downtime are expected to be fulfilled in Q2.
  • Overall, the company is optimistic about good growth and order execution in the near term, viewing short-term softness as exceptional rather than indicative of longer-term trends.

Rossari Biotech Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹685 Cr, net profit ₹46 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Rossari Biotech Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

  • Archean Chemical Industries Ltd (Q1 FY26)

    Q1 FY26 standalone EBITDA grew 13% YoY to INR 958 million with 33% margin; consolidated net profit stood at INR 401 million. Key concall takeaways from Archean…

  • PCBL Chemical Ltd (Q1 FY26)

    Plant closures in Europe/North America may open export opportunities, boosting international sales beyond the current 41% mix. Key concall takeaways from PCBL…

  • Rain Industries Ltd (Q1 FY26)

    Carbon segment capacity utilization is around 68%, with efforts to increase utilization underway. Key concall takeaways from Rain Industries's Q1 FY26 earnings…

  • Styrenix Performance Materials Ltd (Q1 FY26)

    Thailand plant utilization is at 50-55% with potential to increase revenue by 70-80% by ramping up capacity and improving product mix. Key concall takeaways…

Compare:vs Solar Industries India Ltdvs Pidilite Industries Ltdvs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Rossari Biotech Ltd Q1 FY26 results?

Rossari Biotech expects mid-double-digit revenue growth of around 14%-15% annually over the next 2 years. Rossari Biotech expects mid-double-digit (14%-15%) growth in both revenue and EBITDA over the next 2 years (Page 8).

What is Rossari Biotech Ltd share price analysis?

Rossari Biotech Ltd currently shows a neutral. The stock trades at a P/E of 18.5 with a market cap of ₹2,786 Cr. Investors should review the full earnings analysis for detailed insights.

Is Rossari Biotech Ltd planning capital expenditure?

Ongoing capacity expansion projects across Rossari Biotech, Unitop Chemicals, and Tristar Intermediates progressing in phases. - These expansions aim to eliminate capacity constraints, enhance supply chain agility, and strengthen positioning in high-growth sectors. - Commissioning of new capacities expected in upcoming quarters, with full operation and optimal utilization anticipated by FY27, delivering 3x-4x asset turns. - An overseas formulation facility is being set up in Southeast Asia with an initial CAPEX of around Rs.

Keep Rossari Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.